Sensitization of a human ovarian cancer cell line to temozolomide by simultaneous attenuation of the Bcl-2 antiapoptotic protein and DNA repair by O6-alkylguanine-DNA alkyltransferase

Molecular Cancer Therapeutics

Volumn 3, Issue 10, 2004, Pages 1215-1220

  Barvaux, Vincent A ^a   Lorigan, Paul ^b   Ranson, Malcolm ^b   Gillum, Amanda M ^c   McElhinney, R Stanley ^d   McMurry, T Brian H ^d   Margison, Geoffrey P ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c Genta Inc   (United States)

^d TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

6 O ALKYLGUANINE DNA ALKYLTRANSFERASE; 6 O ALKYLGUANINE DNA ALKYLTRANSFERASE INHIBITOR; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; INHIBITOR OF APOPTOSIS PROTEIN; LOMEGUATRIB; OBLIMERSEN; OLIGONUCLEOTIDE; PROTEIN BCL 2; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CONTROL; CANCER INHIBITION; CARCINOGENESIS; CONTROLLED STUDY; DNA ALKYLATION; DNA REPAIR; DRUG POTENCY; DRUG SENSITIZATION; DRUG TARGETING; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; GENE SEQUENCE; HUMAN; HUMAN CELL; MISMATCH REPAIR; OVARY CANCER; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; CELL LINE, TUMOR; DACARBAZINE; DNA REPAIR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; OLIGONUCLEOTIDES; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; TETRAZOLIUM SALTS; THIAZOLES; THIONUCLEOTIDES; TIME FACTORS; UP-REGULATION;

EID: 7444261398     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. 6-alkylguanine-DNA alkyltransferase: role in carcinogenesis and chemotherapy. BioEssays 2002; 24:255-66.
2. Glassner BJ, Weeda G, Allan JM, et al. DNA repair methyltransferase (Mgmt) knockout mice are sensitive to the lethal effects of chemotherapeutic alkylating agents. Mutagenesis 1999;14:339-47.
3. 6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumor cells. Br J Cancer 1993;67:1299-302.
4. Friedman HS, Dolan ME, Pegg AE, et al. Activity of temozolomide in the treatment of central nervous system tumor xenografts. Cancer Res 1995;55:2853-7.
5. 6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc Natl Acad Sci U S A 1990;87:5368-72.
6. 6-(hetarylmethyl)guanines having basic rings in the side chain. J Med Chem 1998;41:5265-71.
7. 6-(4-bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts. Int J Cancer 2000; 85:248-52.
8. Middleton MR, Margison GP. Improvement of chemotherapy efficacy by inactivation of a DNA-repair pathway. Lancet Oncol 2003;4:37-44.
9. Gerson SL. Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 2002;20:2388-99.
10. Reed JC. Bcl-2: prevention of apoptosis as a mechanism of drug resistance. Hematol Oncol Clin North Am 1995;9:451-73.
11. Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol 1999;17: 2941-53.
12. Wintersberger U. Ribonucleases H of retroviral and cellular origin. Pharmacol Ther 1990;48:259-80.
13. Klasa RJ, Gillum AM, Klem EK, Frankel AR. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev 2002;12:193-213.
14. 6-alkylguanine-DNA alkyltransferase assay. Methods Mol Biol 2000;152:49-61.
15. Guesdon JL, Ternynck T, Avrameas S. The use of avidin-biotin interaction in immunoenzymatic techniques. J Histochem Cytochem 1979;27:1131-9.
16. Plumb JA. Cell sensitivity assays: clonogenic assay. In Brown R, Boger-Brown U. editors. Cytotoxic drug resistance mechanisms. Totowa (NJ): Humana Press; 1999. p. 17-23.
17. 6-methylguanine is Bcl-2 and caspase-9/3 regulated and Fas /caspase-8 independent. Cancer Res 2000;60:5815-24.
18. 6-methylguanine in human lymphocytes requires DNA replication and is mediated by p53 and Fas/CD95/Apo-1. Oncogene 2004;23: 359-67.
19. 6-methylguanine-DNA methyltransferase activity in human tumors. Carcinogenesis 1992;13:1503-7.
20. 6-alkylguanine-DNA-alkyltransferases. Curr Gene Ther 2002; 2:1-8.
21. Webb A, Cunningham D, Cotter F, et al. Bcl-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 1997;349:1137-41.
22. O'Brien KR, Byrd J, Cunningham C, Freytes C, Frankel SR, Keating MJ. Bcl-2 antisense (Genasense™) as monotherapy for patients with refractory chronic lymphocytic leukemia [abstract 3213]. Blood 2001; 98:772A.
23. Morris MJ, Tong W, Cordon-Cardo C, et al. A phase I trial of Bcl-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res 2002;8:679-83.
24. Marcucci G, Byrd JC, Catalano SR, et al. Significant disease response to Genasense™ (G3139, Genta), a Bcl-2 antisense, in combination with chemotherapy in refractory or relapsed acute leukemia: a phase I study [abstract 139]. Presented at: American Academy Cancer Research-National Cancer Institute-European Organization for the Research and Treatment of Cancer International Conference; October 29 - November 2, 2001.
25. Rudin CM, Otterson GA, Mauer AM, et al. A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. Ann Oncol 2002;13:539-45.
26. Janssen B, Wacheck V, Heere-Ress E, et al. Chemosensitization of malignant melanoma by bcl2 antisense therapy. Lancet 2000;356: 1728-33.
27. Hauschild A. Global prospective-randomized trial on dacarbazine with or without bcl-2 antisense oligonucleotides for advanced metastatic melanoma [abstract 64]. Presented at: International Conference on Cancer Therapeutics, Molecular Targets, Pharmacology, and Clinical Applications; February 19-21, 2004.